We further demonstrated that RIPK1/RIPK3/MLKL-dependent signaling is required for TNF-α and gemcitabine-induced necroptosis upon IAP depletion and caspase inhibition; therefore, our findings provide new insights toward designing a novel necroptosis-based therapeutic approach for CCA patients. This evidence concerns the gene RIPK1 and cholangiocarcinoma.